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Summary
INTRODUCTION: It is recognised that vitamin D status is
often inadequate (<50 nmol/l) in epileptic children, mainly
because some anticonvulsant drugs induce the enzymes re-
sponsible for its metabolism. The purpose of the present
study was to address vitamin D status among children and
adolescents treated with anticonvulsant drugs and control
subjects who reside in southern Switzerland, a high solar
radiation region.
METHODS: Between January and May 2013, total serum
25-hydroxyvitamin D was assessed by liquid
chromatography-tandem mass spectrometry in 58 children
and adolescents with epilepsy and 29 controls residing in
southern Switzerland. Dark-skinned individuals, females
wearing dress styles covering practically the whole body
and subjects with body mass index ≥85th percentile for age
and sex were excluded.
RESULTS: Concentration of serum 25-hydroxyvitamin D
was similar in epilepsy patients (48 [37–62] nmol/l; median
and interquartile range) and controls (53 [47–64] nmol/l).
An inadequate serum 25-hydroxyvitamin D concentration
was common both among patients (55%) and control sub-
jects (34%). Serum 25-hydroxyvitamin D was significantly
lower among patients treated with anticonvulsant drugs
that induce the metabolism of vitamin D (30 [21–51] nmol/
l) than among the remaining patients (51 [40–65] nmol/l)
and controls.
CONCLUSIONS: The present study indicates a relevant
tendency towards inadequate vitamin D status among chil-
dren with and without anticonvulsant drug management
who reside in southern Switzerland. This tendency is more
prominent in patients treated with anticonvulsant drugs that
induce the metabolism of 25-hydroxyvitamin D.
Keywords: Anticonvulsant drugs; carbamazepine;
childhood; epilepsy; oxcarbazepine; phenobarbital;
phenytoin; vitamin D status; vitamin D supplementation
Introduction
In childhood, vitamin D is crucial for bone growth and
mineralisation because it promotes the assimilation of nu-
tritional calcium and phosphate. New research indicates
that the benefits of vitamin D extend to the musculoskeletal
system as a whole [1–5]. Furthermore, vitamin D might
also play a role in susceptibility to diabetes, cancer, in-
fections and cardiovascular, neurologic or psychiatric dis-
eases. Finally, it might modulate the inflammatory path-
ways [1–5]. As a consequence, the 25-hydroxyvitamin D
blood concentration of ≥25 nmol/l that was thought to be
indicative of “health” in the early 1970s is currently con-
sidered inadequate [5].
It has been recognised since the 1970s that vitamin D status
is often poor in epileptic children, mainly because some an-
ticonvulsant drugs such as carbamazepine, oxcarbazepine,
phenobarbital and phenytoin induce the enzymes respons-
ible for the metabolism of 25-hydroxyvitamin D, resulting
in its increased conversion into inactive metabolites [6–10].
In addition, sun exposure might often be low in epileptic
children concurrently affected with developmental delay
or cerebral palsy. Nonetheless, epileptic patients are only
rarely supplemented with this vitamin [7, 10].
The purpose of the present study was to address vitamin
D status among children and adolescents treated with anti-
convulsant drugs residing in southern Switzerland, a high
solar radiation region [5]. Since recent data suggest that, al-
though overt vitamin D deficiency is no longer common,
lesser degrees of hypovitaminosis D are widespread, a con-
trol group was included.
Subjects and methods
All epileptic patients 2 to 20 years of age on anticonvulsant
drug therapy, who received no vitamin D supplementation
and were on regular follow-up at the Department of Pedi-
atrics, Ente Ospedaliero Cantonale Ticinese, were eligible
for enrollment in the trial. They had to meet all of the fol-
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lowing criteria to qualify for participation: anticonvulsant
drug treatment for ≥12 months, stable drug management
and absence of seizure activity for ≥4 months, as well as
absence of liver or kidney disease. Eligible for the study
as controls were also non-pharmacologically treated chil-
dren with functional voiding disorders, idiopathic child-
hood nephrotic syndrome cured for ≥2 years, attention de-
ficit hyperactivity disorder, or admitted for minor surgical
procedures ( e.g., inguinal hernia repair, phimosis surgery
or hydrocelectomy) in a ratio of 1:2 cases to epilepsy pa-
tients.
Vitamin D status was assessed exclusively in epilepsy pa-
tients and controls for whom a blood collection was
ordered for medical reasons independent of the study.
Dark-skinned individuals, female adolescents wearing
dress styles covering practically the whole body and sub-
jects with body mass index ≥85th percentile for age and sex
were excluded both from the study group and the control
group [5].
The epileptic disease was categorised as “associated” in pa-
tients who also had developmental delay or cerebral palsy
and as “isolated” in those without these difficulties. Liquid
chromatography-tandem mass spectrometry, which quant-
itatively measures both 25-hydroxyvitamin D2 and
25-hydroxyvitamin D3, was applied for the determination
of total 25-hydroxyvitamin D concentration, as previously
reported [11]. Between-run coefficients of variation were
4.6% at a 25-hydroxyvitamin D3 concentration of 69
nmol/l and 4.4% at a 25-hydroxyvitamin D3 concentration
of 145 nmol/l, respectively [11]. A total 25-hydroxyvitamin
D level <50 nmol/l was considered inadequately low [1, 5].
The study design had been approved by the local Ethics
Committee and written informed consent was obtained.
The D’Agostino-Pearson omnibus test for normality
demonstrated that most numerical data are not sampled
from a Gaussian distribution. Numerical data are presented
as median and interquartile range, categorical data as re-
lative frequency. Statistical evaluations included the two-
tailed Kruskal-Wallis test with the Dunn’s post hoc test,
regressions (with the rank correlation coefficient), and the
Fisher exact test [12]. P <0.05 was accepted to indicate stat-
istical significance [12].
Results
Between January and May 2013, 58 Swiss-Italian patients
with epilepsy, 33 affected by “isolated” and 25 affected by
“associated” epilepsy, and a group of 29 controls entered
the study (table 1). The 58 patients were on treatment with
one (N = 43), two (N = 13) or three (N = 2) anticonvulsant
drugs. Age and body weight were significantly (Kruskall-
Wallis test; P <0.01) lower in controls than in patients. On
the contrary, concentration of serum 25-hydroxyvitamin
D was similar in the study group and in controls.
25-hydroxyvitamin D2 level was always ≤6 nmol/l both
in patients and controls. Patients with “isolated” and pa-
tients with “associated” epilepsy significantly differed with
respect to age and weight but not with respect to serum
25-hydroxyvitamin D concentration. An inadequate serum
25-hydroxyvitamin D concentration was common among
control subjects (34%), patients with “associated” (52%)
and patients with “isolated” (58%) epilepsy (without any
significant difference between the groups; Fisher exact
test). Serum 25-hydroxyvitamin D was similar (Kruskal-
Wallis test) in female and male patients (47 [39–60] versus
48 [31–64] nmol/l), in female and male controls (55
[48–70] versus 53 [45–59] nmol/l) and age-independent
(regression analysis) both in controls and epilepsy patients.
Serum 25-hydroxyvitamin D was similar (Kruskal-Wallis
test) in 16 control subjects admitted for minor surgical pro-
cedures (53 [47–66] nmol/l) and in the remaining 13 con-
trol subjects (53 [45–66] nmol/l).
Serum 25-hydroxyvitamin D concentration was signific-
antly lower (P <0.03; Kruskal-Wallis test) in 17 patients on
treatment with at least one drug that induces the metabol-
ism of vitamin D (carbamazepine, oxcarbazepine, pheno-
barbital or phenytoin) as compared with the remaining 41
patients and the 29 controls (fig. 1 and table 2). Patients
managed with drugs that induce the metabolism of vitamin
D were significantly older (Kruskal-Wallis test) than the
remaining patients (P <0.05) and the control subjects (P
<0.01).
Discussion
The present investigation was performed among children
and adolescents on anticonvulsant drug management and
control subjects residing in Southern Switzerland between
January and May, i.e., during a season of the year with low
solar exposure. It indicates that serum 25-hydroxyvitamin
D concentration is inadequate in approximately half of the
participants. Unsurprisingly, the tendency to hypovitamin-
osis D was more pronounced in epileptic patients on drugs
that induce vitamin D metabolism. However, the concen-
tration of 25-hydroxyvitamin D was similar in patients with
and without developmental delay or cerebral palsy, sug-
gesting a similar solar exposure in these two groups of pa-
Figure 1
25-hydroxyvitamin D concentration in 29 controls, in 41 epilepsy
patients without drugs that induce the metabolism of vitamin D and
in 17 patients treated with at least one drug that induces vitamin D
metabolism (carbamazepine, oxcarbazepine, phenobarbital or
phenytoin). The results are given both as individual values as well
as "box and whiskers plot" (the bottom and top of the box are the
25th and 75th centile, the middle of the box is the 50thcentile, i.e.,
the median, the ends of the whiskers represent the 5th and the 95th
centile). The horizontal dotted line denotes the adequacy threshold
level of 50 nmol/l.
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tients. It is therefore concluded that in the winter half-year,
solar radiation is often insufficient to maintain the vitamin
D level in our region. In the summer half-year exposure of
arms, hands and face 2 to 3 times a week for 10–20 minutes
is believed to be adequate to maintain vitamin D level [5].
There is some controversy regarding the best methodology
for assessing 25-hydroxyvitamin D concentration in clinic-
al practice. In this study, 25-hydroxyvitamin D was meas-
ured using liquid chromatography-tandem mass spectro-
metric analysis, a robust technology that is more accurate
than immunological assays [13, 14].
This study was performed in a high solar radiation region.
The substantial advancement over recent preceding work
[15] was the inclusion of a control group of healthy chil-
dren and adolescents, whose 25-hydroxyvitamin D level
was similar to that found on anticonvulsant drugs. It has
been often stated that vitamin D supplementation is imper-
ative in children and adolescents on long-term antiepileptic
drugs [6–10, 15]. That is true, but our results suggest that
all children and adolescents residing in southern Switzer-
land are at risk, at least during winter months, to have an
inadequate level of 25-hydroxyvitamin D. Similar obser-
vations were recently made among healthy Italian children
[16] and among Swiss children with type 1 diabetes mel-
litus residing in a rather low solar radiation region [17].
Standards for defining vitamin D adequacy in children are
not well established. X-ray changes of rickets and reduced
bone density have been observed at 25-hydroxyvitamin
D levels of <40 nmol/l and alkaline phosphatase levels
have been noted to rise at levels <50 nmol/l [1–5]. Hence,
for this study we used the adequacy threshold level of
≥50 nmol/l, recommended among others by the Drug and
Therapeutics Committee of the Lawson Wilkins Pediatric
Endocrine Society and the German Nutrition Society [1].
There is little evidence from studies in children that vitamin
D levels ≥75 nmol/l are necessary, as suggested by some
authorities, including among others the Canadian Pediatric
Society and the Italian Society for Osteoporosis, Mineral
Metabolism and Bone Diseases [1–5].
Table 1: Clinical data and antiepileptic drug management in 58 pediatric patients with epilepsy and 29 control patients. Numerical data are presented as median and
interquartile range, categorical data as relative frequency.
Epilepsy PatientsControl subjects
All “Isolated” “Associated”
N 29 58 33 25
Gender, male to female 16:13 34:24 19:14 15:10
Age, years 4.8 [2.9–6.2] 12.2* [7.3–17.3] 11.5** [7.5–14.6] 15.7**, # [6.1–18.1]
Body weight, kg 16.9 [13.9–21.0] 52.4* [26.0–68.3] 45.0** [26.0–61.9] 55.5**, # [32.0–71.1]
Total serum 25-hydroxyvitamin D
Concentration, nmol/l 53 [47–64] 48 [37–62] 48 [37–66] 47 [32–61]
Concentration <50 nmol/l, N (%) 10 (34) 32 (55) 19 (58) 13 (52)
Drug treatment
Carabamazepine, N – 10 5 5
Oxcarbazepine, N – 3 0 3
Phenytoin, N – 1 0 1
Phenobarbital, N – 3 1 2
Clobazam, N – 2 0 2
Ethosuximide, N – 7 6 1
Lamotrigine, N – 9 5 4
Levetiracetam, N – 5 2 3
Stiripentol, N – 1 0 1
Sultiam, N – 4 4 0
Topiramate, N – 6 2 4
Valproic acid, N – 23 14 9
Vigabatrin, N – 1 0 1
* P <0.01 and ** P<0.03 versus control subjects (Kruskal-Wallis test); # P<0.05 versus patients with “isolated” epilepsy (Kruskal-Wallis test).
Table 2: Clinical data in 41 epileptic patients without and 17 with drugs that induce the metabolism of vitamin D (carbamazepine, oxcarbazepine, phenobarbital or
phenytoin). Numerical data are presented as median and interquartile range, categorical data as relative frequency.
Without inducer of vitamin D
metabolism
With inducer of vitamin D metabolism Significance
N 41 17
Gender, male to female 25:16 9:8 Not significant#
Age, years 11.9 [7.2–15.7] 16.8 [10.1–18.5] P <0.05*
Body weight, kg 47.3 [24.3–61.9] 52.7 [35.0–68.7] Not significant*
Total serum 25-hydroxyvitamin D
Concentration, nmol/l 51 [40–65] 30 [21–51] P <0.03*
Concentration <50 nmol/l, N (%) 20 (49) 12 (71) Not significant*
Epilepsy type
“Isolated” 26 7
“Associated” 15 10
# Fisher exact test; * Kruskal-Wallis test.
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A limitation of our study is that we were not able to assess
the 25-hydroxyvitamin D concentration in patients on an-
ticonvulsants and in healthy subjects matched for age and
gender in a ratio of 1:1 cases. Nonetheless, in this study
25-hydroxyvitamin D levels were age and gender inde-
pendent both in epilepsy patients and controls. Further-
more, considering that in general vitamin D levels are
lower in adolescence [1–5], the inclusion of a well-matched
control group would not have relevantly modified the res-
ults. Another limitation is the heterogeneity of the drugs
used in our patients and the resulting small case numbers
for each drug. Moreover, the distinction in two groups
regarding the effect on vitamin D metabolism (inducers
versus non-inducers) is to some extent arbitrary as induc-
tion of metabolism may occur to different extents.
In conclusion, the present study indicates a relevant tend-
ency towards inadequate vitamin D status among children
without and with anticonvulsant drug management residing
in southern Switzerland, a high solar radiation region. The
tendency, which deserves further confirmation in a larger
and better-designed trial, is slightly more pronounced in
epileptic patients treated with drugs that induce the meta-
bolism of 25-hydroxyvitamin D. This alarmingly high pre-
valence of hypovitaminosis D in the general pediatric pop-
ulation during the winter and spring warrants action at a
population level rather than at a risk group level [1–5,
18]. The recommendation that Swiss infants receive a sup-
plementation of 400 units of vitamin D3 per day during
the first 12 months of life has been recently extended [5].
Nowadays, 600 units of vitamin D3 per day are recommen-
ded also for the second and third year of life and 600 units
per day exclusively during the winter and spring for older
children and adolescents [5]. Based on our data, this sup-
plementation might well be advised also for epileptic chil-
dren. For children and adolescents managed with drugs that
induce vitamin D, year-round vitamin D supplementation
might seem appropriate. At our institutions we also advise
screening of 25-hydroxyvitamin D level in the latter pa-
tients, considering that for every 100 units of added vitamin
D3, 25-hydroxyvitamin D concentration is expected to in-
crease by approximately 2–3 nmol/L [1, 5].
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Figures (large format)
Figure 1
25-hydroxyvitamin D concentration in 29 controls, in 41 epilepsy patients without drugs that induce the metabolism of vitamin D and in 17
patients treated with at least one drug that induces vitamin D metabolism (carbamazepine, oxcarbazepine, phenobarbital or phenytoin). The
results are given both as individual values as well as "box and whiskers plot" (the bottom and top of the box are the 25th and 75th centile, the
middle of the box is the 50thcentile, i.e., the median, the ends of the whiskers represent the 5th and the 95th centile). The horizontal dotted line
denotes the adequacy threshold level of 50 nmol/l.
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